Merck & Co Inc

NYSE:MRK   3:59:58 PM EDT
73.36
-0.25 (-0.34%)
5:18:37 PM EDT: $73.44 +0.08 (+0.11%)
Products, Regulatory

OSE Immunotherapeutics: First Patient Randomized In Phase 2 Clinical Trial Of Tedopi

Published: 08/26/2021 16:09 GMT
Merck & Co Inc (MRK) - Ose Immunotherapeutics and Arcagy-gineco Announce First Patient Randomized in Phase 2 Clinical Trial Evaluating Tedopi® in Combination With Pembrolizumab in Ovarian Cancer.
Clinical Trial Sponsored and Conducted by French Oncology Cooperative Group Arcagy-gineco and Supported by Merck Sharp & Dohme Corp.
(msd).
First Results Expected Beginning of 2025.
Three Arm Tedova Study Aims at Evaluating Neo-epitope-based Vaccine Tedopi As a Maintenance Treatment, Alone Or in Combination.